RxDoctor Payments Data

Malcolm Ing, MD

Ophthalmology · Honolulu, HINPI 1588701080

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.

$5,691in general payments, 2019–2025

Across 91 payments — averaging $62.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Dompe US, Inc.$534
  • Regeneron Healthcare Solutions, Inc.$481
  • Amgen$444
  • AbbVie$417
  • Genentech USA, Inc.$394
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,691 in reported general payments places this provider in the 70th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$42,154
Medicare patients
138
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate26$8,746
Latanoprost67$1,641
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$1,011
Timolol Maleate20$185

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →